Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* metastatic RCC with majority (\>50%) of conventional clear-cell type;~* prior total nephrectomy for primary RCC;~* at least one measurable or non-measurable lesions;~* ECOG performance score of 0 or 2.~Exclusion Criteria:~* prior systemic treatment for metastatic RCC;~* current or previously treated but non-stable CNS metastases or spinal cord compression;~* major surgery (including open biopsy) or radiation therapy within 28 days prior to enrollment;~* significant cardiovascular disease within 6 months prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).